US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Alamar Biosciences (ALMR): Bio-Platform Company Scales, Draws Heavy IPO Interest

Alamar Biosciences (ALMR): Scarcity and Growth Power Strong First-Day Rally for Proteomics Platform

Alamar Biosciences (ALMR): Peeking at the IPO Prospectus of a Protein Detection & Analysis Biotech

IPOs and Secondary Offerings

Equity Capital Markets

Alamar Biosciences / Equity Capital Markets

<ul>
<li>IPO terms set for $15.00–$17.00 per share, targeting ~$1.1B valuation and ~$133M in proceeds to scale commercial, manufacturing, and R&amp;D operations.</li>
<li>Commercial-Stage proteomics company generating $74.2M revenue in 2025, leveraging proprietary NULISA platform for ultra-sensitive biomarker detection across research and diagnostics.</li>
<li>Strong investor backing and momentum with $300M+ raised, Qiming Ventures as largest holder (16.2%), and IPO expected to trade April 17.</li>
</ul>


IPO terms set for $15.00–$17.00 per share, targeting ~$1.1B valuation and ~$133M in proceeds to scale commercial, manufacturing, and R&amp;D operations.
Commercial-Stage proteomics company generating $74.2M revenue in 2025, leveraging proprietary NULISA platform for ultra-sensitive biomarker detection across research and diagnostics.
Strong investor backing and momentum with $300M+ raised, Qiming Ventures as largest holder (16.2%), and IPO expected to trade April 17.


Alamar Biosciences (ALMR): Revenue Generating Protein Detection Platform Sets Terms for IPO